If this message does not appear correctly, click this link

Speeches & Conferences

Nov 28    Upcoming Asia Pacific Lung Cancer Forum

ACT Genomics and Taiwan Lung Cancer Society will hold Asia Pacific Lung Cancer Forum on November 28th at Taipei W hotel. Medical specialists with abundant experiences using NGS multi-gene panel  from Asia Pacific region will be invited to discuss the differences between Western and Eastern lung cancer treatment and the NGS genetic testing application in lung cancer treatment in Asia. Welcome to join us!

Image title

Nov 10-11  Last Call to Register for The Upcoming Annual 5th Hong Kong International Oncology Symposium (5th HKIOS)

ACT Genomics has the invaluable opportunity to be one of the sponsors of the 5th Hong Kong International Oncology Symposium (5th HKIOS) from 10th -11th November 2018 at Hong Kong Science and Technology Park (HKSTP) and City University of Hong Kong (CityU) respectively. The event is co-organized by many first-class medical and academic institutes in the Guangdong-Hong Kong-Macao Greater Bay area that aims to provide an international platform to foster long-term collaborative relationships among them. The 5th HKIOS will highlight the  new core technologies in Precision Oncology particularly Single Cell Sequencing, Personalized Immunotherapy, Cancer Genomics, Artificial Intelligence & Big Data, Thoracic Oncology & Precision Radiotherapy. We are excited to see you at the 5th HKIOS! For detailed information and enrollment, please visit http://www.hkpos.org/

Image title

Nov 09    Friends of Cancer Research Will Present Initial Findings of TMB Hamonization  in Washinton, D.C. 

To ensure consistency when evaluating immunotherapy for patients, Friends of Cancer Research has launched the TMB (Tumor mutational burden) harmonization project convened major stakeholders to create standardization for TMB calculation and reporting across different testing panels. ACT Genomics is proud to be the only molecular diagnostic company from Asia. TMB Harmonization oral presentation titled “In silico assessment of variation in TMB quantification across diagnostic platforms: Phase 1 of the Friends of Cancer Research Harmonization Project “ is scheduled on November 9 th from 12:15 – 12:30 p.m. in 33rd Annual Meeting & Pre-Conference Programs (SITC 2018) at the Walter E. Washington Convention Center in Washington, D.C.

 Nov 07-11    ACT Genomics Shares Precision Medicine in Immunotherapy at SITC 2018

The 33rd Annual Meeting & Pre-Conference Programs (SITC 2018) held by The Society for Immunotherapy of Cancer (SITC) is one of the important events in immunotherapy, which gathers cancer experts specialized in immunotherapy around the world. SITC 2018 aims to promote the progress of immunotherapy by multiple academic workshops and interactive activities. ACT Genomics will introduce how innovative genomic profiling services can improve immunotherapy reponse rate with predictive biomarkers such as tumor mutational burden (TMB) at booth # 209.

Image title

 Nov 07    Educational Lecture at Kiang Wu Hospital, Macau on NGS Application to Guide Targeted & Immune Therapeutics by Lab Director of ACTG HK

Next Generation Sequencing (NGS) is a powerful technology that can sequence hundreds to thousands of cancer associated biomarkers. With the discovery of more and more gene targets associated with treatment response to anti-cancer drugs, NGS is, nowadays, turning into clinical use to help clinicians, especially clinical oncologists, to find appropriate targeted & immune drugs for treatment of cancer patients. ACT Genomics Hong Kong Laboratory Director, Dr. Timothy T.C. Yip will deliver a talk titled “The New Frontier in Precision Oncology Treatment: How Next-Generation Sequencing (NGS) testing can guide the use of targeted & immune drugs in treatment of cancer patients?” Dr. Timothy T.C. Yip has professional experiences as Adjunct Professor, City University of Hong Kong; Visiting Professor in University of Missouri, USA; Honorary Associate Professor, SPACE, University of Hong Kong.
 In this seminar, the audiences will be briefed in:
(1). The latest druggable gene targets which are useful for treatment of lung cancer, breast cancer, ovarian cancer and colorectal cancer patients.
(2). The current paradigm shift to use large NGS panel rather than serial small PCR panels to recommend targeted drugs – example in lung cancer.
(3). What laboratory indices (PD-L1, MSI & TMB etc.) we currently used to examine responsiveness to immune check point drugs (e.g. PD1, PD-L1 or CTLA4 inhibitor drugs).
(4). Emerging supplementary biomarkers useful in determining drug response in cancer treatment.

 Nov 06   Upcoming Public Medical Talk: "Where We Stand with Immunotherapy in Lung Cancers" by Dr. Jacky Li

ACT Genomics is proudly sponsoring a medical talk to be given by Dr. Li Yu Chung, Jacky, consultant and specialist in Clinical Oncology from Hong Kong United Oncology Centre, on lung cancer management and immunotherapy at the Hong Kong Playground Association on November 6th 2018. Early diagnosis and treatment can help lung cancer patients conquer fear and find new hope.

Image title

 Oct 30    ACT Genomics Scientific Talk at Gleneagles Medini Hospital, Malaysia

ACT Genomics was honoured to be invited to give a scientific talk at Gleneagles Medini Hospital, Johor, Malaysia on 30th October 2018. Dr. Liisa discussed how precision medicine is changing the field of cancer management and how CGP has risen to the forefront by dissecting the highly complex composition of cancer.

 Oct 27    Upcoming Nurse Training Course on Medical Genetics Genetic Counselling in Oncology

An educational course for oncology nurses on Medical Genetic for Cancer took place on 27th October 2018. The course was co-organized by Hong Kong Society of Medical Genetics and ACT Genomics. Speakers included Dr. Lam Tak Sum, Stephen, Director, Clinical Genetics Service, Hong Kong Sanatorium & Hospital; Dr. Ho-Ming Luk, Specialist in Genetics and Genomics (Paediatrics) ; Dr. Wong Hiu Yan, Hilda, Specialist in Medical Oncology ; Dr. Kien-Thiam Tan, PhD, and Zoey Hsu, patient education executive from ACT Genomics. Medical genetics is one of the most rapidly evolving areas in cancer medicine. Precision oncology is a new area of cancer medicine and has introduced a new level of complexity into the practice of cancer risk assessment and management. Oncology providers work at the frontline are responsible to communicate potential benefits, limitations and risks to patients about adopting targeted therapies and accompany diagnostics. This course helps oncology nurses with practical knowledge in providing required counseling to help patients understand rationale and clarify decision of cancer assessment and management between patients and clinical oncologists.

Image title

 Oct 24    Singapore Industry Night - Spotlight on Technology and Business

What are some trending hot-button issues faced by government affairs professionals within the technology and business sectors as government stakeholders in Asia ramp up their respective Smart Nation initiatives? These issues were discussed in the "Industry Night – Spotlight on Technology and Business" event organised by Lee Kuan Yew School of Public Policy. This event will feature panels of government affairs professional from the healthcare, pharmaceutical and technology organizations. Some topics that may be discussed by the panel include: designing the roadmap for success when trying to digitalize healthcare services and how to best address regulatory and compliance issues when planning one’s market entry strategy in Asia. Dr. Allen Lai, Senior VP of ACT Genomics was honoured to be invited as one of the panellist and speaker from the biotech industry.

Image title

Oct 21    ACT Genomics Supported The Flagship Annual Charity Fundraising Pink Walk For Breast Health 2018 at The Peak

On Oct 21st, whole team of ACT Genomics HK joined “Pink Walk for Breast Health", which is the flagship annual fundraising event for the non-profit charitable organisation Hong Kong Breast Cancer Foundation (HKBCF). The Pink Walk has been held for 13 consecutive years. The dedication of HKBCF to "mitigating the threat of breast cancer to the local community through education, patient support and research & advocacy" resonates strongly with ACT Genomics’ belief that it is important to promote public awareness of breast health and advocate better breast cancer care in Hong Kong. HKBCF recently published its research data that shows, besides non-modifiable risk factors such as family history of breast cancer, genetic predisposition and previous benign breast diseases etc; suffer of mental stress by a woman, which previously was classified as a probable risk factor, could impose a greater risk than familial inheritance.  ACT Genomics welcome more events and collaboration between diagnostic industries and health education NGOs to increase cancer awareness.

Image title

 Oct 19-23    ACT Genomics Presented Precision Medicine Findings in ESMO 2018 Congress

ACT Genomics was proud to be selected for abstract poster presentation during the ESMO 2018 Congress starting from 19th till 23rd October at Munich, Germany. In this presentation, we presented our study in exploring the differences between liquid biopsy and tissue-based genomic tests in Asian lung cancer patients to guide treatment selection. Although liquid biopsy tests were able to identify a large proportion of lung cancer patients with indications for targeted therapy, tissue-based testing outperformed liquid biopsies for most therapeutic indications, suggesting that tissue-based testing remains the gold standard for treatment selection.

Image title

Oct 18   Public Medical Talk on Treating Lung Cancer by Frontline Immunotherapies based on Precise Classification and Genetic Analysis

Dr. Angus Leung’s medical talk was organized by Health Action and sponsored by ACT Genomics at the Hong Kong Cultural Centre. Dr. Leung shared his experiences that comprehensive cancer profiling tests have become more popular and more affordable nowadays. Dr. Leung highlighted the rapid development in personalised medicine and precision medicine, meanwhile it is important to educate the general public to have reasonable expectation on these advanced technologies such as liquid biopsy tests. Dr. Leung’s talk was a comprehensive update on the application of immunotherapies, especially its benefit in enhanceing survival rates of lung cancer patients with relatively mild side effects. He later shared that with a positive result of common lung cancer driver gene detected using a high quality genetic testing, targeted therapies can be applied instead of conventional chemotherapies. Therefore, it is essential to choose genetic services with consistently high standard to guide targeted and immunotherapies, in order to ensure a positive clinical outcome from the right treatment.

Image title

Oct 12    ACT Genomics Gave Plenary Talk in 32nd Best of ASCO Annual Meeting at Mandaluyong City, Philippines

ACT Genomics was honoured to be invited to give plenary talk at the 32nd Best of ASCO Annual Meeting at EDSA Shangri-La Hotel, Mandaluyong City, Philippines on 12th October 2018. This event was co-organised by Philippine Society of Medical Oncology and American Society of Clinical Oncology.  Dr. Maarja-Liisa Nairismägi presented the key findings from the ASCO 2018 Annual Meeting on "Liquid Biopsy to Identify Actionable Genomic Alterations" and "Novel Platforms and Clinical Applications for Non-invasive Molecular Testing".

Image title

Oct 07-08   ACT Genomics and Hong Kong Precision Oncology Society (HKPOS) Visited Guangdong Lung Cancer Insititute, Guangdong Academy of Medical Sciences and General Hospital (GGH)

ACT Genomics was invited to visit Guangdong Academy of Medical Sciences and General Hospial (GGH) alongside with Hong Kong Precision Oncology Society (HKPOS) on 7th-8th   October. GGH is one of the largest general hospitals in China and has been officially selected as one of the participating hospitals in the "Peak Mounting Plan", a scheme launched this year for the constrcution of a high-standard hospitals in China. The first batch of listed hospitals in the "Peal Mounting Plan" includes 9 hospitals in total, including The University of Hong Kong Shenzhen Hospital (HKU-SZH), The First Affiliated Hospital, Zhongshan (Sun Yat-sen) University, etc.
As one of the co-organizers of the upcoming 5th Hong Kong International Oncology Symposium (5th HKIOS; 10th-11th November 2018), it was our distinct honour to invite Prof. Yi-Long Wu, Vice President of GGH & Chief of Guangdong Lung Cancer Institute, and Prof. Gui-Bin Qiao, Director & Professor, Depart. of Thoracic Surgery, GGH, to attend as the event’s VIP speakers.

Besides this 2-day Guangzhou visit, ACT Genomics and HKPOS had a fruitful discussion on research interest and future prospect in precision oncology with GGH representatives. We look forward to having more collaborative opportunities with these world-class clinical oncology experts in China in the near future.

Image title

Oct 05    ACT Genomics  Precision Cancer Care Talk at Davao, Philippines

ACT Genomics proudly presented the symposium themed “Precision Cancer Care” at Seda Abreeza Hotel, Davao City on 5th October 2018. This high-level symposium has brought together more than 20 over medical oncologists, hematologists, and pathologists from the Davao region. We were very honoured to have Dr. Alex Alegrado, Medical Director of ARC Oncology Group (Cebu) leading a series of didactic, interactive, and cancer-based case sharing sessions with topic titled “Clinician experience: Real world clinical challenges and the application of genomic information to precision cancer management”. Dr. Allen Lai, Senior VP of ACT Genomics also shared his insight on “Precision Cancer Care in the Philippines: Diagnostics Perspective”. Followed by Dr. Poon, MSL of ACT Genomics presented topic on “Precision medicine: Cancer Diagnostic tools, from Past to Present”.

Image title

Oct 01-04     ACT Genomics Presented Precision Medicine Findings in 2018 World Cancer Congress

ACT Genomics was delighted to announce that we had 2 abstracts accepted for e-poster presentation at the 2018 World Cancer Congress (WCC). As an initiative of UICC - Union for International Cancer Control and hosted by the National Cancer Society Malaysia, the 2018 Congress took place from 1st - 4th October in the Kuala Lumpur Convention Centre (KLCC). Dr. Maarja-Liisa Nairismägi shared one of our studies demonstrating that a cancer hotspot panel, compared to a large comprehensive genomic profiling (CGP), is sufficient to identify actionable alterations and TKI resistance mechanisms in most Asian lung cancer patients. These findings will benefit the patients by allowing cost saving as the price of CGP differs based on panel size. On the other hand, Dr. Poon presented data findings on identifying actionable alterations across different solid tumors using comprehensive genomic profiling.

Image title

 Sep 27    ACT Genomics Scientific Talk at National Cancer Hospital in Hanoi, Vietnam

ACT Genomics was honoured to be invited to give a scientific talk at the National Cancer Hospital in Hanoi, Vietnam. Sharing case studies on how information provided by Comprehensive Genomic Profiling (CGP) can be beneficial for treatment selection in chemo, targeted, hormonal and immunotherapies.

Image title

 Sep 25-29    ACT Genomics Joined National Taiwan University Hospital Delegation Trip to Yogyakarta & Jakarta

ACT Genomics was honoured to participate in National Taiwan University Hospital (NTUH) delegation trip to Yogyakarta & Jakarta from 25th-29th September 2018. Commissioned by Taiwan Ministry of Health and Welfare, this delegation trip has brought collaboration opportunities between Indonesia and Taiwan in the medical & healthcare field.

Image title

Sep 19-23   ACT Genomics Attended The 21st Chinese Society of Clinical Oncology (CSCO) Annual Meeting at Xiamen China

This fall, ACT Genomics attended the 21st Annual Meeting of Chinese Society of Clinical Oncology (CSCO), organized by CSCO and Beijing Xisike Clinical Oncology Research Foundation. The CSCO Annual Meeting attracted the most participants in Asia and presented the latest advancement and fruitful research on clinical oncology in China. This year, famous experts both at home and abroad were invited to gather at Xiamen International Conference and Exhibition Center on September 19th - 23rd  2018, to give lectures on the prevention, diagnosis, treatment and nursing in the management of cancers.

The theme of this year’s meeting is "Opening a New Era of Cancer Patient Care Through Vigorous Clinical Research" and the successful event reflected the remarkable academic level in precision oncology through a multidisciplinary, collaborative approach among Chinese Clinical Oncology. ACT Genomics took this inspiring opportunity to get exposed to the latest technological advances,  exchange latest cancer care strategy, R&D experiences and seek out potential collaboration with different parties.

Image title


 ACT Genomics Finished A New Fundraising Round in The Wave of  Medical Market Growth 

Global medical market grows at the rate of 7% steadily, and the  compound annual growth rate is expected to reach 19% in 2030 with the explosive potential in precision medicine. ACT Genomics Holdings Company Limited focusing on cancer genomic profiling services has recently finished a new fundraising round with international investors from Hong Kong, Singapore and Japan, which will accelerate the speed of internationalization. Full text : https://money.udn.com/money/story/11800/3412613

Image title


Image title

FDA Approves Anti-PD-1 Antibody Cemiplimab for CSCC

Abstract :The U.S. FDA approves PD-1 inhibitor cemiplimab-rwlc (Libtayo) for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC).     See more...

Image title

Repotrectinib Shows Significant Clinical Activity in ROS1+ NSCLC

Abstract : In the phase I/II TRIDENT-1 study, repotrectinib demonstrates a clinically meaningful response in non-small cell lung cancer (NSCLC) patients carrying ROS1 fusion.  See more...

Image title

Brigatinib Shows Promising Results as First Line for ALK+ Lung Cancer

Abstract : In the phase 3 ALTA-1L study, brigatinib significantly prolongs the progression-free survival (PFS) compared to crizotinib in adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC).   See more...

Image title

PARP/Immunotherapy Combo Offers New Opportunities in Ovarian Cancer

Abstract : There are limited treatment options in platinum-resistance/refractory ovarian cancer patients. The phase I/II TOPACIO/KEYNOTE-162 study shows that the combination of PARP inhibitor and a PD-1 inhibitor can achieve response in difficult-to-treat patients.   See more...

Image title

The Next-Generation Sequencing Data Revealed The Prevalence of Homologous Recombination–related Gene Mutations in Multiple Cancer Types

Abstract : The scientists analyzed the prevalence of homologous recombination–related gene mutations across 21 cancer types. The sequencing data indicated that these genes were commonly mutated in endometrial, biliary tract, and bladder cancer. The results revealed a new path for developing new treatment strategies.  See more...

Please do not reply to this email as it is sent from a non-monitored account. To contact us, please email service@actgenomics.com.

  To unsubscribe, please enter your E-Mail :